Compile Data Set for Download or QSAR
Report error Found 63 Enz. Inhib. hit(s) with all data for entry = 3207
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394203(US9975876, 28)
Affinity DataIC50: 18nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394200(US9975876, 25 | ethyl 4-methoxy-2-{[(3R,6R)-6- met...)
Affinity DataIC50: 19.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394205(US9975876, 30)
Affinity DataIC50: 25nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394206(US9975876, 31)
Affinity DataIC50: 25nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394185(US9975876, 7 | methyl 2-{[(3R,6R)-1-{[5-fluoro-2- ...)
Affinity DataIC50: 27.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394199(US9975876, 23)
Affinity DataIC50: 27.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394189(US9975876, 11 | methyl 2-{[(3R,6R)-1-{[3-fluoro-2-...)
Affinity DataIC50: 31.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM341136(US9765057, 3 | methyl 4-(methylsulfanyl)-2- {[(3R,...)
Affinity DataIC50: 33nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394181(US9975876, 3 | methyl 2-{[3R,6R)-1-{[4-chloro-2- (...)
Affinity DataIC50: 33.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394191(US9975876, 13 | methyl 2-{[(3R,6R)-1-{[5-fluoro-2-...)
Affinity DataIC50: 34.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394210(US9975876, 35 | methyl 2-methoxy-6-({(3R,6R)-6- me...)
Affinity DataIC50: 35nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394187(US9975876, 9 | methyl 2-{[3R,6R)-1-{[5-fluoro-2- (...)
Affinity DataIC50: 36.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394180(US9975876, 2 | US9975876, 19)
Affinity DataIC50: 37nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394192(US9975876, 14 | methyl 4-methoxy-2-{[(3R,6R)-6- me...)
Affinity DataIC50: 37.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394195(US9975876, 18 | methyl 2-{[(3R,6R)-1-{[3-fluoro-2-...)
Affinity DataIC50: 39.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394201(US9975876, 26 | ethyl 2-{[3R,6R)-1-{[3-fluoro-2-(2...)
Affinity DataIC50: 39.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394209(US9975876, 34 | methyl 2-methoxy-6-({(3R,6R)-6- me...)
Affinity DataIC50: 42nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394193(US9975876, 15 | methyl 4-methoxy-2-{[(3R,6R)-1-{[4...)
Affinity DataIC50: 51nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394183(US9975876, 5 | methyl 2-{[(3R,6R)-1-{[4-fluoro-2- ...)
Affinity DataIC50: 52nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394204(US9975876, 29)
Affinity DataIC50: 52nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394194(US9975876, 17 | methyl 4-methoxy-2-{[(3R,6R)-1-{[6...)
Affinity DataIC50: 52nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394188(US9975876, 10 | methyl 2-{[(3R,6R)-1-{[4-fluoro-2-...)
Affinity DataIC50: 58.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394207(US9975876, 32 | methyl 2-methoxy-6-{[(3R,6R)-6- me...)
Affinity DataIC50: 61nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394186(US9975876, 8 | methyl 2-{[(3R,6R)-1-{[2-fluoro-6- ...)
Affinity DataIC50: 71.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394197(US9975876, 21 | methyl 2-({(3R,6R)-1-[(4-fluoro-2-...)
Affinity DataIC50: 71.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394184(US9975876, 6 | methyl 2-{[(3R,6R)-1-{[2-fluoro-6- ...)
Affinity DataIC50: 82.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394180(US9975876, 2 | US9975876, 19)
Affinity DataIC50: 114nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394198(US9975876, 22 | methyl 2-({(3R,6R)-1-[(3-fluoro-2-...)
Affinity DataIC50: 117nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394202(US9975876, 27)
Affinity DataIC50: 167nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394208(US9975876, 33 | methyl 2-methoxy-6-{[(3R,6R)-6- me...)
Affinity DataIC50: 202nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394182(US9975876, 4 | methyl 2-{[(3R,6R)-1-{[4-fluoro-2- ...)
Affinity DataIC50: 764nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394192(US9975876, 14 | methyl 4-methoxy-2-{[(3R,6R)-6- me...)
Affinity DataIC50: 777nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394200(US9975876, 25 | ethyl 4-methoxy-2-{[(3R,6R)-6- met...)
Affinity DataIC50: 814nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394195(US9975876, 18 | methyl 2-{[(3R,6R)-1-{[3-fluoro-2-...)
Affinity DataIC50: 932nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394191(US9975876, 13 | methyl 2-{[(3R,6R)-1-{[5-fluoro-2-...)
Affinity DataIC50: 1.16E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM341136(US9765057, 3 | methyl 4-(methylsulfanyl)-2- {[(3R,...)
Affinity DataIC50: 1.34E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394181(US9975876, 3 | methyl 2-{[3R,6R)-1-{[4-chloro-2- (...)
Affinity DataIC50: 1.42E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394185(US9975876, 7 | methyl 2-{[(3R,6R)-1-{[5-fluoro-2- ...)
Affinity DataIC50: 1.46E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394197(US9975876, 21 | methyl 2-({(3R,6R)-1-[(4-fluoro-2-...)
Affinity DataIC50: 1.47E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394187(US9975876, 9 | methyl 2-{[3R,6R)-1-{[5-fluoro-2- (...)
Affinity DataIC50: 1.50E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394180(US9975876, 2 | US9975876, 19)
Affinity DataIC50: 1.87E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394199(US9975876, 23)
Affinity DataIC50: 2.14E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394189(US9975876, 11 | methyl 2-{[(3R,6R)-1-{[3-fluoro-2-...)
Affinity DataIC50: 2.27E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394184(US9975876, 6 | methyl 2-{[(3R,6R)-1-{[2-fluoro-6- ...)
Affinity DataIC50: 2.31E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394201(US9975876, 26 | ethyl 2-{[3R,6R)-1-{[3-fluoro-2-(2...)
Affinity DataIC50: 2.79E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394180(US9975876, 2 | US9975876, 19)
Affinity DataIC50: 2.90E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394183(US9975876, 5 | methyl 2-{[(3R,6R)-1-{[4-fluoro-2- ...)
Affinity DataIC50: 3.10E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394182(US9975876, 4 | methyl 2-{[(3R,6R)-1-{[4-fluoro-2- ...)
Affinity DataIC50: 3.20E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394198(US9975876, 22 | methyl 2-({(3R,6R)-1-[(3-fluoro-2-...)
Affinity DataIC50: 3.78E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM394203(US9975876, 28)
Affinity DataIC50: 4.13E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2020
Entry Details
US Patent

Displayed 1 to 50 (of 63 total ) | Next | Last >>
Jump to: